Physician profile
Kamran Rasul
NPI 1356306591
$2,258.21
in general payments reported to CMS, 2019-2025
22 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $448 · 2021: $475 · 2022: $178 · 2023: $294 · 2024: $351 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $206.68 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $185.14 | 2020-2021 | |
| Amgen INC. | $181.28 | 2019-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $180.69 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $180.06 | 2019-2020 | |
| Medtronic Minimed, INC. | $141.84 | 2019 | |
| Horizon Therapeutics Plc | $132.09 | 2021 | |
| Dexcom, INC. | $73.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $62.06 | 2024 | |
| Beta Bionics, INC. | $45.05 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $44.01 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.96 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $39.70 | 2020-2023 | |
| Xeris Pharmaceuticals, INC. | $27.22 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.76 | 2020 | |
| Ibsa Pharma INC. | $24.57 | 2020 | |
| Medtronic, INC. | $17.09 | 2023 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $16.64 | 2020 | |
| Merck Sharp & Dohme LLC | $14.47 | 2020 | |
| Medtronic USA, INC. | $14.36 | 2019 | |
| Shire North American Group INC | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Rasul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.